Form 14 Under the Income-tax Act, 2025: A Clear and Updated Guide
The introduction of Form 14 under the Income-tax Act, 2025 marks a significant shift in how companies claim tax benefits for in-house research and development (R&D). This updated framework replaces the earlier system and brings greater structure, accountability, and transparency to R&D-related tax deductions.
What is Form 14?
Form 14 is an approval order issued by the Department of Scientific and Industrial Research (DSIR). It is granted under Section 45(2) of the Income-tax Act, 2025 read with Rule 29 of the Income-tax Rules, 2026. The form certifies that a company’s specific in-house R&D facility is eligible for consideration under the tax deduction framework.
It is important to note that Form 14 is not filed by the taxpayer. Instead, it is issued by DSIR after a detailed evaluation of the R&D facility.
Compliance Lifecycle
The process to obtain and utilize Form 14 is part of a structured compliance chain:
- Form 11 – Application and agreement submitted by the company
- DSIR recognition and technical evaluation
- Form 14 – Approval order issued by DSIR
- Form 12 – Reporting by DSIR
- Form 13 – Audit report by an accountant
- Income-tax assessment – Final decision on deduction
This lifecycle ensures that approval, reporting, and verification are all interconnected.
Key Features of Form 14
Form 14 approval is facility-specific. It applies only to the R&D unit evaluated by DSIR, not to the entire company. If a company operates multiple R&D facilities, each may require separate approval.
The approval is based on prior DSIR recognition, and its validity is tied to the recognition period. The form typically includes details such as the company’s business, R&D objectives, facility location, and reference to DSIR recognition.
Most importantly, Form 14 does not grant a tax deduction by itself. It only establishes eligibility. The actual deduction depends on multiple factors including expenditure, audit compliance, and assessment by tax authorities.
Eligibility and Conditions
To claim a deduction, companies must ensure that:
- The R&D activity qualifies as scientific research
- The research is related to the business carried on
- All expenses are genuine and properly documented
- DSIR conditions and prescribed rules are followed
This framework mainly applies to sectors such as pharmaceuticals, manufacturing, engineering, and technology, where structured R&D activities are common.
Revocation of Approval
Form 14 approval is not permanent. It can be withdrawn if:
- DSIR recognition expires or is cancelled
- There is non-compliance with rules
- The R&D activity is found to be non-genuine
This makes ongoing compliance critical for companies.
Key Change from the Previous System
Under the earlier regime, companies relied on Section 35 and Form 3CM. The new system under Section 45(2) with Form 14 introduces a more integrated and verification-driven approach. It reduces ambiguity and strengthens coordination between DSIR, auditors, and tax authorities.
Practical Impact on Businesses
The updated framework creates a stricter entry barrier, allowing only genuine R&D facilities to qualify. Companies now need to maintain detailed documentation, including project records, expense tracking, and audit trails.
There is no longer a direct link between approval and deduction. Instead, deduction depends on a combination of approval, compliance, audit, and verification. This approach reduces misuse and makes the system more robust and litigation-resistant.
Conclusion
Form 14 serves as a critical gateway in the modern R&D tax deduction framework. It establishes eligibility but does not guarantee tax benefits. Companies must follow a comprehensive compliance process, maintain accurate records, and undergo proper audit and verification to claim deductions.
Overall, the new system strengthens accountability, aligns with global standards, and ensures that only genuine R&D efforts receive tax incentives.